“The smallest RX at a 5.25-inch profile, still extremely high MOI with adjustable weight, adjustable lie, and Cure's T-Bar alignment. Face-balanced for a straight stroke without the largest footprint.”
The RX3 is the compact end of Cure's RX lineup, a Florida-brand answer to the high-MOI mallet trend built for golfers who want maximum stability without the largest possible footprint. At 5.25 inches heel-to-toe it's the smallest RX shape, machined from aircraft-grade aluminum with a full weight kit (two 12g aluminum and two 35g steel toe/heel discs) that lets a fitter dial MOI from roughly 6,700 up to 12,800 by swapping in denser weights. The hosel is fully adjustable for lie from 62 to 80 degrees, and Cure paired it with a simple two-circle alignment aid. It's a face-balanced, straight-back-straight-through tool aimed squarely at forgiveness rather than shot-shaping, sold direct and through fitters rather than chasing tour pros or pro-shop shelf space.
No forum-reverence cult narrative, but Cure has real standing in the high-MOI mallet niche: it's covered in recurring buyer's guides (Golf Tips, Golf Monthly forum threads), independently reviewed by outlets like Plugged In Golf and ColoradoGolfBlog, and its adjustable-weight/adjustable-lie combo is genuinely differentiated versus fixed-weight mallets from bigger brands. It sells consistently to a specific audience (seniors, high-handicappers, players managing wrist or back issues who want a heavier, more stable putter) rather than the broad market.
Built for golfers who want a smaller-profile mallet than the RX4/RX5 but still want adjustable weight and lie for a straight-back stroke — good for players who found the bigger Cure heads visually oversized at address. Not for anyone who wants to work the putter face open/closed through the stroke or prefers a toe-hang blade feel; the face-balanced design fights that.
Launched into the mid-2010s high-MOI mallet wave alongside Odyssey's Ten/Jailbird, TaylorMade Spider, and Bettinardi's Studio Stock mallets, but Cure differentiated on adjustability (interchangeable weights and a full lie-adjustable hosel) rather than face-insert technology. It predates the current Spider/Ten dominance of tour bags and stayed a fitter/direct-sale niche product rather than breaking into mainstream retail the way those rivals did.
Genuinely very forgiving: a reviewer called it 'literally the most forgiving putter available,' noting it barely twists on mis-hits even at its lighter weight settings and that forgiveness climbs further as you add mass. It sits a notch below the largest RX4/RX5 shapes in the same family simply because the 5.25-inch head has less raw MOI ceiling (~12,800 vs. the RX5's 18,000) — forgiveness within this specific product line scales directly with head size.
Calibrated across the whole catalog — a tour blade scores low here on purpose; it means control, not ease.
Realistic 2026 private-party price is roughly $90-150 — Cure is a real but small brand, so demand and resale liquidity are both modest compared to Odyssey/TaylorMade/Scotty mallets at similar retail. Original MSRP was $259; expect the low end for well-worn examples and the top end for near-new units with the full weight kit included.
Reading is one thing — hitting is another. Book a bay and see the numbers for yourself before you buy anywhere.
